genetic technologies (asx: gtg, nasdaq global market: gene) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of dna on health. throughout the asia pacific region, we translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.
Company profile
Ticker
GENE
Exchange
Website
CEO
Jerzy Muchnicki
Employees
Location
Industry (SIC)
Former names
GENETIC TECHNOLOGIES LTD /FI
SEC CIK
GENE stock data
Latest filings (excl ownership)
6-K
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
17 Apr 24
6-K
Current report (foreign)
11 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
GTG Secures Short Term Loan Facility with Radium Capital
26 Mar 24
6-K
Current report (foreign)
25 Mar 24
6-K
GTG to develop Worlds Most Advanced Comprehensive Risk Test
22 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Current report (foreign)
7 Mar 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
20 Feb 24
Transcripts
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G
CVI Investments, Inc.
13 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
4 Jun 20
SC 13G
INTRACOASTAL CAPITAL, LLC
28 Apr 20
SC 13G/A
Genetic Technologies LTD
13 Feb 19
SC 13G
Genetic Technologies LTD
14 Feb 18
SC 13G/A
Genetic Technologies LTD
9 Feb 18
SC 13G/A
Genetic Technologies LTD
8 Jan 18
SC 13G/A
Genetic Technologies LTD
14 Feb 17
SC 13G/A
Genetic Technologies LTD
10 Feb 17
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 6 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 268.32 mm |
Total shares | 706.24 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 623.08 mm | $0.00 |
Intracoastal Capital | 83.03 mm | $166.90 mm |
MS Morgan Stanley | 87.66 k | $66.85 mm |
Rhumbline Advisers | 18.70 k | $14.38 mm |
Two Sigma Securities | 15.84 k | $12.08 mm |
Scarborough Advisors | 10.64 k | $8.11 mm |
Proequities | 0.00 | $0.00 |
News
Genetic Technologies Announced Tuesday, It Established Precision Oncology Division, Announced geneType Precision Oncology Brand Portfolio Of New Diagnostic Tests
17 Apr 24
Cannabis Stock Gainers And Losers From April 16, 2024
16 Apr 24
Bearish Monday For Marijuana Stocks - AusCann Group Holdings, Target Group Among Top Gainers
15 Apr 24
Cannabis Stock Movers For April 12, 2024
12 Apr 24
Marijuana Stock Movers For April 11, 2024
11 Apr 24
Press releases
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
12 Apr 24
GTG to pilot GeneType in Breast Screen centers across the U.S.
11 Apr 24
Genetic Technologies' Digital Strategy Ignites Significant Traction in US Market
2 Apr 24
GTG Global Collaborations and Innovation Update
26 Mar 24